Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ultragenyx UX001 receives orphan drug designation
UX001 is an extended release formulation of sialic acid intended as a substrate replacement therapy for HIBM which is caused due to sialic acid deficiency. The company initiated
UX001 is an extended release formulation of sialic acid intended as a substrate replacement therapy for HIBM which is caused due to sialic acid deficiency. The company initiated
Ridaforolimus is an investigational oral mTOR inhibitor to treat metastatic soft-tissue or bone sarcomas in patients who responded to chemotherapy. The European Medicines Agency had earlier accepted the
TZP-102 is an orally-administered promotility agent used to treat diabetic gastroparesis as it targets the ghrelin receptor, which plays a direct role in the stimulation of GI motility.
FDA intends to improve drug safety, cut health care costs and create jobs through this move. The grant will support programs to rectify drug development and manufacturing problems.
The double-blind, dose-response, randomized study enrolled 279 patients to five study arms BCX4208 at doses of 5 mg, 10 mg, 20 mg, 40 mg and placebo, administered once-daily
The SLS 500i prevents intravenous medication errors via barcode assisted medication labelling. The barcode assisted syringe labelling technology scans drug vial barcodes, and prints a full-colour label containing
Sitavir is a mucoadhesive buccal tablet used to treat recurrent orofacial herpes in immunocompetent patients presenting more than 4 episodes a year. The drug delivers high concentrations of
Evotec will make use of its drug discovery expertise and technologies to identify small molecules against a selected number of targets, which will be progressed through lead optimization
Cariprazine is an antipsychotic agent used to treat acute mania associated with bipolar I disorder. This Phase III, multicenter, double-blind, placebo- controlled, parallel-group study evaluated the efficacy, safety,
Myogane, a small molecule drug is used as a neuro-protectant treatment of glaucoma, which is a neurodegenerative disease of the eye affecting. Current treatments of glaucoma are predominantly